Utilization of the Oncotype Dx Assay for Young Patients with Early Stage, Hormone-Receptor Positive, HER2-Negative Breast Cancer in an Integrated Health System

被引：0
|
作者：
Aller, Ashley
Darbinian, Jeanne A.
Liu, Raymond
Kuehner, Gillian
Savitz, Alison
Odele, Patience
Habel, Laurel
Vuong, Brooke
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-01-27
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-01-27
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [42] Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer
    Olsson, Linnea T.
    Hamilton, Alina M.
    Van Alsten, Sarah C.
    Lund, Jennifer L.
    Sturmer, Til
    Nichols, Hazel B.
    Reeder-Hayes, Katherine E.
    Troester, Melissa A.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (01) : 107 - 116
  • [43] Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey
    Fekih, Mahmoud
    Petit, Thierry
    Zarca, Daniel
    Guinebretiere, Jean-Marc
    Andre, Fabrice
    Pierga, Jean-Yves
    Namer, Moise
    Gligorov, Joseph
    Delaloge, Suzette
    BULLETIN DU CANCER, 2014, 101 (10) : 918 - 924
  • [44] A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
    Christine Brezden-Masley
    Kelly E. Fathers
    Megan E. Coombes
    Behin Pourmirza
    Cloris Xue
    Katarzyna J. Jerzak
    Breast Cancer Research and Treatment, 2021, 185 : 507 - 515
  • [45] A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
    Brezden-Masley, Christine
    Fathers, Kelly E.
    Coombes, Megan E.
    Pourmirza, Behin
    Xue, Cloris
    Jerzak, Katarzyna J.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (02) : 507 - 515
  • [46] Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer
    Lee, Su Hyun
    Ha, Seunggyun
    An, Hyun Joon
    Lee, Jae Sung
    Han, Wonshik
    Im, Seock-Ah
    Ryu, Han Suk
    Kim, Won Hwa
    Chang, Jung Min
    Cho, Nariya
    Moon, Woo Kyung
    Cheon, Gi Jeong
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (09) : 1574 - 1584
  • [47] Methods for selection of neoadjuvant treatment with chemotherapy for patients with hormone receptor-positive and HER2-negative with early breast cancer.
    Gasol Cudos, Ariadna
    Morales Murillo, Serafin
    Tuset Der-abrain, Noemi
    Arbones Cid, Laura
    Morera Morillo, Ester
    Vilardell, Felip
    Sanchez Guzman, Douglas
    Canosa Morales, Carles
    Mele Olive, Jordi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] A SYSTEMATIC LITERATURE REVIEW OF THE ECONOMIC BURDEN AMONG PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
    Salvo, E.
    Fogarty, S.
    da Silva, Aniceto C.
    Samjoo, I. A.
    Cueto, J.
    Law, E.
    VALUE IN HEALTH, 2020, 23 : S34 - S34
  • [49] Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer
    Su Hyun Lee
    Seunggyun Ha
    Hyun Joon An
    Jae Sung Lee
    Wonshik Han
    Seock-Ah Im
    Han Suk Ryu
    Won Hwa Kim
    Jung Min Chang
    Nariya Cho
    Woo Kyung Moon
    Gi Jeong Cheon
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 1574 - 1584
  • [50] A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer
    Harbeck, Nadia
    Burstein, Harold J.
    Hurvitz, Sara A.
    Johnston, Stephen
    Vidal, Gregory A.
    CANCER, 2022, 128 : 2209 - 2223
12345